PDF
(Download)
|
- Turmeric (Curcuma longa)
- Curcumin
- Bioactivity
|
Date:
07-15-2013 | HC# 061361-476
|
Re: The Bioactivity of Curcumin – an Active Constituent of Turmeric
Witkin
JM, Li X. Curcumin, an active constiuent [sic]
of the ancient medicinal herb Curcuma
longa L.: some uses and the establishment and biological basis of medical
efficacy. CNS Neurol Disord Drug Targets.
April 4, 2013;12(4):1-11.
Turmeric
(Curcuma longa) root is used around
the world in a multitude of traditional medicine systems1 and is
reported to be used for digestive problems, as an anti-inflammatory, and
topically.1 In traditional Chinese medicine, turmeric is part of a
combination used for the alleviation of stress and dyspepsia, among other
conditions. Curcumin is the compound considered to be central to the
bioactivity of turmeric. This review summarizes research on the bioactivity of
curcumin.
Curcumin
is thought to work via the inflammation, cell death, and oxidative stress
processes. Previous studies have shown curcumin to have anticancer properties;
it halts the growth of tumors and modulates secondary problems such as fatigue,
depression, and sleep issues. Curcumin has also been shown to quench reactive
oxygen species and to attenuate nuclear factor-kappaB (NF-ĸB), an immune and
inflammatory signaling agent. In vivo, curcumin halted protein expression linked
to the regulation of cell growth and survival, tumor proliferation, and angiogenesis,
and induced apoptosis. The activation of signal transducer and activator of
transcription 3 (STAT3), upstream of cancer growth, was also attenuated by
curcumin. Additionally, damage caused by stroke has also been improved by
curcumin.
Curcumin
has been reported to be active in alleviating a host of inflammation-related
conditions including multiple sclerosis, rheumatoid arthritis, psoriasis, and
others. This is thought to be due to the modulation of cytokines, a class of
inflammation signalers. Curcumin also attenuates glutamate production, the
overexpression of which can be disruptive. Furthermore, curcumin has also been
shown to prevent the buildup of amyloid-β plaques, which is correlated with
Alzheimer's disease.
Other
studies with acute and chronic curcumin administration in vivo have shown that curcumin
has biological mechanisms of action against both stress and depression. These
mechanisms include the modification of neurotransmission, modulation of cell
signaling, decrease of oxidative stress, and promotion of endogenous
neuroprotection. Studies have also reported that curcumin modulates signaling
upstream of mood problems; and that curcumin activates neurogenesis, which is a
potential target for treating mood and depression. In vivo, curcumin also benefitted
learning.
Curcumin
has been investigated clinically for a variety of treatments in both healthy
and unhealthy subjects. A dose of 8 g daily of curcumin caused no serious adverse
side effects, with only nausea and diarrhea being reported; however, curcumin
has demonstrated limited bioavailability when taken orally. A clinical study in
patients with colorectal cancer reported benefits on body weight. When used
along with standard medications in patients with inflammatory bowel disease, positive
effects were seen in symptoms, and medication dosages were lowered or ended. In
a study of patients with prediabetes, oral administration of curcumin prevented
the onset of diabetes and improved β-cell function, insulin sensitivity, and
inflammation markers, as compared to those in the placebo group.
The
authors address the potential improvement of poor bioavailability of oral forms
of curcumin as an important future research direction. In general, curcumin has
little solubility in water, low absorption, and a brief half-life. Possible
solutions to these problems are the production of analogs, the combination of
curcumin with other compounds, and/or modifying the delivery of curcumin, such
as using liposomal or phospholipid mixtures and incorporating nanoparticles. A
combination of curcumin with other compounds found in turmeric (BCM-95®
CG; Frutarom Health; Haifa, Israel) improved bioavailability by seven times
above that of curcumin by itself.
In
conclusion, curcumin has been found to have a range of bioactivity, both in
vivo and clinically. Mechanisms of action for much of the bioactivity have also
been elucidated. Further studies will ideally improve the oral bioavailability
of curcumin, and additional clinical trials could confirm the usage of curcumin
in treating myriad diseases and conditions.
—Amy C. Keller, PhD
Reference
1Blumenthal M,
Goldberg A, Brinckmann J, eds. Herbal
Medicine: Expanded Commission E Monographs. Austin, TX: American Botanical Council; Newton, MA: Integrative
Medicine Communications; 2000.
|